J. Stern

发表

Successful treatment of extensive condyloma acuminata of the inguinal area and thigh with topical imiquimod cream.

J. Weinberg, A. Stewart, J. Stern, 2001, Acta dermato-venereologica.

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.

D. Dieterich, P. Robinson, J. Stern, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Faldaprevir and pegylated interferon &agr;-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

C. Tural, D. Dieterich, J. Rockstroh, 2015, AIDS.

Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection

M. Omata, A. Taniguchi, S. Nishiguchi, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Open‐label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1‐infected patients who failed placebo plus peginterferon and ribavirin

T. Asselah, J. Dufour, P. Ferenci, 2016, Journal of viral hepatitis.

Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND‐C3, a Phase 2b study

M. Buti, J. Dufour, S. Zeuzem, 2015, Liver international : official journal of the International Association for the Study of the Liver.

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.

T. Asselah, D. Ouzan, J. Dufour, 2015, Journal of hepatology.

STARTVerso 1 : A randomized trial of faldaprevir plus pegylated interferon / ribavirin for chronic HCV genotype-1 infection q

T. Asselah, D. Ouzan, J. Dufour, 2015 .

Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis

M. Manns, M. Buti, T. Asselah, 2014, Antimicrobial Agents and Chemotherapy.

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

T. Asselah, B. Leggett, G. Kukolj, 2013, Hepatology.

Faldaprevir and deleobuvir for HCV genotype 1 infection.

M. Buti, T. Asselah, V. Soriano, 2013, The New England journal of medicine.

Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results

T. Asselah, F. Zoulim, P. Angus, 2013, Antiviral Therapy.

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

M. Buti, G. Kukolj, C. Sarrazin, 2016, Clinical and experimental gastroenterology.

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

T. Asselah, J. Pawlotsky, G. Kukolj, 2013, Hepatology.

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

M. Buti, T. Asselah, A. Lohse, 2015, PloS one.

A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

D. Mayers, M. Imperiale, S. Lanes, 2003, Journal of acquired immune deficiency syndromes.

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

T. Berg, T. Asselah, D. Dieterich, 2014, Antimicrobial Agents and Chemotherapy.

101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2

M. Buti, T. Asselah, G. Kukolj, 2012 .

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

T. Asselah, F. Zoulim, P. Angus, 2011, Gastroenterology.

66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

T. Asselah, J. Pawlotsky, S. Pol, 2011 .

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

T. Asselah, B. Leggett, S. Mauss, 2011 .

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.

M. Manns, T. Berg, G. Kukolj, 2011, Journal of hepatology.

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

C. Trautwein, V. de Lédinghen, G. Gerken, 2012, Journal of hepatology.

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

X. Forns, P. Beaulieu, G. Kukolj, 2009, Antiviral therapy.

954 BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAIN

M. Manns, G. Kukolj, S. Pol, 2009 .

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

C. Trautwein, G. Gerken, A. Tran, 2010 .

1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

X. Forns, S. Pol, H. Wedemeyer, 2007 .

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

G. Kukolj, C. Sarrazin, D. Nelson, 2016, PloS one.

Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin

M. Manns, T. Berg, S. Pol, 2009 .

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

C. Trautwein, G. Gerken, A. Lohse, 2010 .

Hepatic profile analyses of tipranavir in Phase II and III clinical trials

D. Dieterich, J. Rockstroh, S. Pol, 2009, BMC Infectious Diseases.

Chronic Hepatitis C Polymerase Inhibitor, in Patients with an Investigational Hepatitis C Virus RNA Administration of Deleobuvir (BI 207127), Pharmacokinetics of Five-Day Oral Antiviral Effect, Safety, and

G. Kukolj, A. Lohse, M. Marquis, 2014 .

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C

G. Kukolj, A. Lohse, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies

G. Kukolj, A. Quinson, J. Stern, 2015, Antimicrobial Agents and Chemotherapy.

HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon

T. Asselah, D. Ouzan, G. Kukolj, 2014 .

O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN

R. Colonno, J. Lalezari, N. Huang, 2014 .

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

G. Kukolj, M. Massariol, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

T. Asselah, J. Pawlotsky, S. Pol, 2010 .

Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients

Qihong Huang, T. Asselah, D. Tweedie, 2014, The Journal of Pharmacology and Experimental Therapeutics.

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

T. Asselah, D. Ouzan, J. Dufour, 2013 .

A Twenty-Eight-Day Mechanistic Time Course Study in the Rhesus Monkey with Hepatitis C Virus Protease Inhibitor BILN 2061

Qihong Huang, B. Knight, R. Seidler, 2011, Toxicologic pathology.

Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial: 487

T. Asselah, J. Dufour, S. Zeuzem, 2013 .

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment

M. Manns, X. Forns, C. Sarrazin, 2016, PloS one.

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study

M. Buti, P. Angus, J. Dufour, 2016, European journal of gastroenterology & hepatology.

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

T. Asselah, D. Ouzan, T. Hassanein, 2016, Annals of hepatology.

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Wei Zhang, Manuel Battegay, Sreeraj Macha, 2011, Clinical therapeutics.

Faldaprevir and deleobuvir for HCV genotype 1 infection.

M. Buti, T. Asselah, V. Soriano, 2013, The New England journal of medicine.